CSL Ltd (CSL) - Financial and Strategic SWOT Analysis Review

September 2021 | 56 pages | ID: CA09B25782BEN
GlobalData

Abstracts

CSL Ltd (CSL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

CSL Ltd (CSL) discovers, develops, manufactures, commercializes and distributes biopharmaceuticals and related products. Its portfolio encompasses plasma-derived products for the treatment of hemophilia, hereditary angioedema, von Willebrand disease, inherited primary and secondary immune deficiencies, respiratory disease, neurological disorders and protein-based medicines for treating serious human illnesses. The company also provides products for the prevention of hemolytic disease in newborns, infection in solid organ transplant recipients and to treat specific infections for victims of trauma and burns. CSL markets an array of vaccines, anti-venoms and pharmaceutical products of various other manufacturers. The company sells its products in Australia, Germany, Switzerland, the UK, the US and other countries. CSL is headquartered in Parkville, Victoria, Australia.

CSL Ltd Key Recent Developments

Aug 17,2021: CSL announces appointment of new non-executive director
Jul 27,2021: Seqirus begins shipping portfolio of innovative vaccines for the 2021/22 U.S. influenza season
Jul 01,2021: Applications open for 2021 CSL Centenary Fellowships
Jun 25,2021: CSL announces resignation of director
Jun 16,2021: CSL: Appointment of new non-executive director

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

CSL Ltd - Key Facts
CSL Ltd - Key Employees
CSL Ltd - Key Employee Biographies
CSL Ltd - Major Products and Services
CSL Ltd - History
CSL Ltd - Company Statement
CSL Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
CSL Ltd - Business Description
Business Segment: CSL Behring
Capital Expenditure
Overview
Performance
Business Segment: Seqirus
Capital Expenditure
Overview
Performance
Geographical Segment: Australia
Performance
Geographical Segment: China
Performance
Geographical Segment: Germany
Performance
Geographical Segment: Rest of World
Performance
Geographical Segment: Switzerland
Performance
Geographical Segment: The UK
Performance
Geographical Segment: The US
Performance
R&D Overview
CSL Ltd - Corporate Strategy
CSL Ltd - SWOT Analysis
SWOT Analysis - Overview
CSL Ltd - Strengths
CSL Ltd - Weaknesses
CSL Ltd - Opportunities
CSL Ltd - Threats
CSL Ltd - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

CSL Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
CSL Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
CSL Ltd, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 17, 2021: CSL announces appointment of new non-executive director
Jul 27, 2021: Seqirus begins shipping portfolio of innovative vaccines for the 2021/22 U.S. influenza season
Jul 01, 2021: Applications open for 2021 CSL Centenary Fellowships
Jun 25, 2021: CSL announces resignation of director
Jun 16, 2021: CSL: Appointment of new non-executive director
Jun 02, 2021: CSL: COVID-19 Update
Jun 01, 2021: Applications Open for 2022 CSL Centenary Fellowships
May 12, 2021: CSL welcomes the introduction of a Patent Box
May 12, 2021: CSL welcomes Government commitment to domestic mRNA vaccine development
Apr 29, 2021: 2020 CSL Research Acceleration Initiative Awardees Announced

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

CSL Ltd, Key Facts
CSL Ltd, Key Employees
CSL Ltd, Key Employee Biographies
CSL Ltd, Major Products and Services
CSL Ltd, History
CSL Ltd, Other Locations
CSL Ltd, Subsidiaries
CSL Ltd, Key Competitors
CSL Ltd, Ratios based on current share price
CSL Ltd, Annual Ratios
CSL Ltd, Annual Ratios (Cont...1)
CSL Ltd, Annual Ratios (Cont...2)
CSL Ltd, Interim Ratios
CSL Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
CSL Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
CSL Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

CSL Ltd, Performance Chart (2017 - 2021)
CSL Ltd, Ratio Charts
CSL Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
CSL Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021